

Report Information

More information from: <https://www.marketresearchfuture.com/reports/intravenous-solution-market-1235>

Intravenous (IV) Solutions Market Research Report - Forecast till 2030

Report / Search Code: MRFR/HC/0727-CR

Publish Date: June, 2021

Request Sample

Price	1-user PDF : \$ 4950.0	Site PDF : \$ 3250.0	Enterprise PDF : \$ 7250.0
-------	------------------------	----------------------	----------------------------

Description:

Global Intravenous Solution Market Overview

The Intravenous solution market Size was valued at USD 6.5 billion in 2021 and is projected to grow from USD 7 Billion in 2022 to USD 11.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8% during the forecast period (2022 - 2030). The key factors driving the expansion of the intravenous solution market include rising chronic disease incidence and prevalence, an aging global population, and rapidly increasing healthcare spending on IV therapy treatment.

Intravenous Solution Market Overview

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Intravenous Solution Market Trends

Growing launches and regulatory approvals for intravenous solution injection to drive growth

New intravenous injection solutions are being introduced by market participants, which is anticipated to accelerate the growth of the global intravenous solutions market in the upcoming years. For example, Baxter International Inc., a global sterile medication production company, announced the FDA approval and commercial launch of premix Bitartrate in 5% Dextrose Injection in September 2021. In adults with severe, acute hypotension, is prescribed to raise blood pressure (low blood pressure). Baxter's formulation is the first and only producer of ready-to-use formulation available in four strengths: 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL).

Parenteral (intravenous) nutrition (PN) product launches by key market players for developing global intravenous solutions are anticipated to propel market growth in the forecast period. For instance, in June 2019, the Indian pharmaceutical market saw the introduction of the intravenous IV products Lifeport and Discport by Eurolife Healthcare, a manufacturer and distributor of specialty infusion & pharmaceuticals. The product, which uses advanced technology to lower the risk of infection, is regarded as a smart intravenous infusion.

The rising prevalence of malnutrition, shorter response time, and higher efficacy associated with intravenous solution therapy have further contributed to expanding the intravenous solution market share.

Intravenous Solution Market Segment Insights:

Intravenous Solution Nutrition Type Insights

Based on the nutrition type, the intravenous solution market segmentation includes peripheral and total parenteral nutrition. The total parenteral nutrition (TPN) segment had the largest share in 2021, accounting for nearly 62-66% of intravenous solution market revenue, owing to higher adoption for patients who do not receive any other form of nutrition. This is brought on by increased gastrointestinal conditions like Ulcerative Colitis (UC) and Crohn's Disease (CD), which prevent patients from absorbing vital nutrients. Therefore, an intravenous route is used to deliver these vital nutrients. The increase in the elderly population, where patients need to be fed nutritionally necessary products via intravenous routes, can also be attributed to segment growth.

Figure 2: Intravenous solution market, by Nutrition Type, 2021 & 2030 (USD Billion)

Intravenous solution market by Nutrition Type 2021 and 2030

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Intravenous Solution Bag Type Insights

Based on the bag type, the intravenous solution market includes large-volume bags (>250 ml) and small-volume bags (<250 ml). The small-volume bags (<250 ml) segment had the largest global market revenue share in 2021. Globally, a rise in patients with various types of infectious diseases is a major factor driving the growth of this segment. They are also becoming more popular in blood bank centers to meet emergency blood infusion needs and treat various blood-borne diseases. In addition, IV fluid bag manufacturers create PVC-free bags made of non-latex elements to safely and accurately deliver IV fluids. Cold, frozen, and customized mixtures can also be stored in these fluid bags.

Intravenous Solution Nutritional Content Insights

Based on the nutritional content, the intravenous solution market segmentation includes amino acid solutions, carbohydrates, vitamins & minerals, parenteral lipid emulsion, and others. The amino acid solution segment had the highest revenue share in 2021, owing to the rising prevalence of nutrient deficiencies and hepatic diseases and higher consumption of amino acid injections. The increased approval of enhanced amino acid solutions with fewer side effects propels the intravenous solution market forward. The increasing utility of parenteral nutrition regimens and single doses based on amino acids in the preparation of intravenous parenteral fluids worldwide is a key factor contributing to the growth of this segment.

Intravenous Solution End User Insights

Based on the end user, the intravenous solution market segment includes hospitals & clinics, ambulatory surgical centers, and home care. The hospital & clinics segment had a significant market revenue share in 2021 due to an increase in the number of hospitals and clinics and an increase in the prevalence of metabolic problems. The growing number of patients who undergo surgical procedures that require IV solutions as a post-therapy routine for various conditions and diseases in hospitals worldwide is expected to drive the Intravenous (IV) Solutions market size during the forecast period.

Intravenous Solution Regional Insights

By Region, the study provides market insights into Europe, North America, Asia-Pacific, and the Rest of the World. The North American intravenous solution market is expected to grow at a significant CAGR during the projection period, accounting for USD 2.8 billion in 2021. This is due to an increase in the geriatric population, which increases demand for intravenous solutions, the rising incidence of chronic diseases, and the industry's expansion to meet the rising demands caused by the flu and coronavirus pandemics. North America is a highly developed region with a well-established healthcare infrastructure, which has resulted in an increased demand for IV treatment throughout its life cycle during various stages, such as emergency care or surgery.

In addition, the major countries covered in the intravenous solution market are the United States, Germany, France, Canada, the United Kingdom, India, Spain, Italy, Japan, Australia, China, South Korea, and Brazil.

Figure 3: INTRAVENOUS SOLUTION MARKET SHARE BY REGION 2021 (%)

INTRAVENOUS SOLUTION MARKET SHARE BY REGION 2021

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe has the world's second-largest intravenous solution market, owing to increasing intravenous solution sales volume in the region due to the region's aging population and correlating growth of the patient pool. This is because the healthcare system has a large patient population, a strong presence of key players, easy drug availability, well-developed healthcare systems, and favorable reimbursement policies. Moreover, technological advancements in the industry and government assistance for the National Health Service and health insurance will likely drive growth in the European intravenous (IV) solutions market. Further, the U.K. intravenous solution market held the largest market share, and the France intravenous solution market was the fastest-growing market in the European region.

The Asia Pacific intravenous solution market is predicted to expand at the fastest CAGR in the forecast period. The presence of high expenditure by both public and private entities in the research sector, as well as technological advancements and an increasing number of collaborative relationships between various stakeholders, such as the healthcare community, universities, and others, can be attributed to this region's rapid growth. Another important factor anticipated to drive market growth in the Asia Pacific region is the rising prevalence of chronic diseases brought on by unhealthy food consumption patterns and the growing preference for cost-effective care.

Intravenous Solution Key Market Players & Competitive Insights

The market players constantly expand their facilities, collaborate, acquire companies, and develop new products. These are major strategic initiatives influencing the dynamics of the intravenous solution industry. Additionally, the prevalence of chronic diseases is rising, offering huge opportunities to manufacturers of intravenous solutions. The main industry players concentrate on research and development activities to release new and effective treatments, accelerating the market's growth.

ICU Medical Inc, headquartered in San Clemente, California, develops, manufactures, and sells medical technologies for oncology, vascular therapy, and critical care applications. Smith's Medical, a division of Smiths Group plc, was acquired by ICU Medical in January 2022. This merger will add Smiths Medical's ambulatory infusion equipment, syringes, vascular access, and medical supplies to ICU Medical's current infusion therapy system, generating an estimated pro forma revenue of about USD 2.5 billion.

The company B. Braun Medical (India) Private Ltd sells medical supplies. The company produces instruments and equipment for medicine, surgery, ophthalmology, diabetes care, infection control, ostomy care, infusion therapy, and veterinary medicine. International customers are served by B. Braun Medical (India). B. Braun Medical received permission from the US FDA in February 2022 to start operations at its brand-new IV saline solution production plant in Daytona Beach, Florida.

Key Companies in the intravenous solution market include

- Baxter International Inc (US)
- Fresenius SE & Co. KGaA (Germany)
- Braun Melsungen AG (Germany)
- ICU Medical Inc (US)
- Pfizer Inc (US)
- Grifols S.A. (Spain)
- Terumo Medical Corporation (Japan)

Intravenous Solution Industry Development

September 2022: B. Braun Medical Inc has introduced CARESAFE IV Administration Sets with an entirely voluntary AirStop component.

October 2020: Pfizer has procured Arixia Pharmaceuticals for its active compound ARX-1796, an intravenous combination used to treat various conditions. It allows patients to leave the hospital sooner and avoids the need for hospital admission.

November 2020: Otsuka Pharmaceutical has introduced ENEFLUID Injection, a peripheral parenteral nutrition solution containing fat and water-soluble electrolytes, glucose, vitamins, and an amino acid solution in a dual-chamber bag.

Intravenous Solution Market Segmentation

Intravenous Solution Nutrition Type Outlook

- Peripheral Parenteral Nutrition
- Total Parenteral Nutrition

Intravenous Solution Bag Type Outlook

- Large Volume Bags (>250 ml)
- Small Volume Bags (<250 ml)

Intravenous Solution End User Outlook

- Hospital & Clinics
- Ambulatory Surgical Centers
- Home Care

Intravenous Solution Nutritional Content Outlook

- Amino Acid Solution
- Carbohydrates
- Vitamins & Minerals
- Parenteral Lipid Emulsion
- Others

Intravenous Solution Regional Outlook

- North America
 - US
 - Canada
- Europe
 - Germany
 - France
 - UK
 - Italy
 - Spain
 - Rest of Europe
- Asia-Pacific
 - China
 - Japan
 - India
 - Australia
 - South Korea
 - Australia
 - Rest of Asia-Pacific
- Rest of the World
 - Middle East
 - Africa

- Latin America

Table of Content:

Contents

TABLE OF CONTENTS	
1 EXECUTIVE SUMMARY	14
2 MARKET INTRODUCTION	15
2.1 SCOPE OF THE STUDY	15
2.2 RESEARCH OBJECTIVE	15
2.3 MARKET STRUCTURE	15
2.4 ASSUMPTIONS & LIMITATIONS	16
3 RESEARCH METHODOLOGY	17
3.1 DATA MINING	17
3.2 SECONDARY RESEARCH	18
3.3 PRIMARY RESEARCH	19
3.4 BREAKDOWN OF PRIMARY RESPONDENTS	20
3.5 FORECASTING TECHNIQUES	21
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION	21
3.6.1 BOTTOM-UP APPROACH	22
3.6.2 TOP-DOWN APPROACH	22
3.7 DATA TRIANGULATION	23
3.8 VALIDATION	23
4 MARKET DYNAMICS	24
4.1 OVERVIEW	24
4.2 DRIVERS	25
4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES	25
4.2.2 RISING INCIDENCES OF CHOLERA	25
4.2.3 GROWING ACCEPTANCE OF VITAMIN C INTRAVENOUS SOLUTIONS FOR COLORECTAL CANCER	25
4.3 RESTRAINT	26
4.3.1 PRESENCE OF STRINGENT GOVERNMENT REGULATIONS	26
4.4 OPPORTUNITY	27
4.4.1 RISING CONTINUOUS DEMAND FOR INTRAVENOUS SOLUTIONS	27
5 MARKET FACTOR ANALYSIS	28
5.1 VALUE CHAIN ANALYSIS	28
5.1.1 R&D AND DESIGNING	29
5.1.2 MANUFACTURING	29
5.1.3 DISTRIBUTION & SALES	29
5.1.4 POST-SALES MONITORING	29
5.2 PORTER'S FIVE FORCES MODEL	29
5.2.1 THREAT OF NEW ENTRANTS	30
5.2.2 BARGAINING POWER OF SUPPLIERS	30
5.2.3 THREAT OF SUBSTITUTES	31
5.2.4 BARGAINING POWER OF BUYERS	31
5.2.5 INTENSITY OF RIVALRY	31
5.3 COVID-19 IMPACT ANALYSIS	31
5.3.1 IMPACT ON THE SUPPLY CHAIN	31
5.3.2 IMPACT ON PRICING	31
5.3.3 IMPACT ON PRODUCTION	32
6 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE	33
6.1 OVERVIEW	33
6.2 PERIPHERAL PARENTERAL NUTRITION	34
6.3 TOTAL PARENTERAL NUTRITION	34
7 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE	35
7.1 OVERVIEW	35
7.2 LARGE VOLUME BAGS (>250 ML)	36
7.3 SMALL VOLUME BAGS (<250 ML)	36
8 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT	37
8.1 OVERVIEW	37
8.2 AMINO ACID SOLUTION	38
8.3 CARBOHYDRATES	38
8.4 VITAMINS & MINERALS	39
8.5 PARENTERAL LIPID EMULSION	39
8.6 OTHERS	40
9 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER	41
9.1 OVERVIEW	41
9.2 HOSPITAL & CLINICS	42
9.3 AMBULATORY SURGICAL CENTERS	42
9.4 HOME CARE	43
10 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY REGION	44
10.1 OVERVIEW	44
10.2 NORTH AMERICA	46
10.2.1 US	48
10.2.2 CANADA	49
10.3 EUROPE	51
10.3.1 GERMANY	53
10.3.2 FRANCE	54
10.3.3 UK	56
10.3.4 ITALY	57
10.3.5 SPAIN	58
10.3.6 REST OF EUROPE	60
10.4 ASIA PACIFIC	62
10.4.1 CHINA	64
10.4.2 INDIA	66
10.4.3 INDONESIA	67
10.4.4 JAPAN	68
10.4.5 PHILIPPINES	70
10.4.6 THAILAND	71

10.4.7 SOUTH KOREA	72
10.4.8 AUSTRALIA	74
10.4.9 SINGAPORE	75
10.4.10 MALAYSIA	76
10.4.11 REST OF ASIA-PACIFIC	78
10.5 REST OF THE WORLD	80
10.5.1 MIDDLE EAST	82
10.5.2 AFRICA	83
10.5.3 LATIN AMERICA	85
11 COMPETITIVE LANDSCAPE	87
11.1 OVERVIEW	87
11.2 COMPETITIVE BENCHMARKING	89
11.3 COMPETITOR DASHBOARD	90
11.4 MAJOR GROWTH STRATEGY IN THE GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET	90
11.5 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET	91
11.6 KEY DEVELOPMENT ANALYSIS	91
11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES	92
11.7.1 PRODUCT LAUNCH/PRODUCT APPROVAL	92
11.7.2 MERGER/ACQUISITION	92
11.7.3 PARTNERSHIP/AGREEMENT	93
11.7.4 EXPANSION/ INVESTMENT	93
12 COMPANY PROFILES	94
12.1 BAXTER INTERNATIONAL INC.	94
12.1.1 COMPANY OVERVIEW	94
12.1.2 FINANCIAL OVERVIEW	95
12.1.3 PRODUCTS/SERVICES OFFERED	96
12.1.4 KEY DEVELOPMENTS	96
12.1.5 SWOT ANALYSIS	97
12.1.6 KEY STRATEGIES	97
12.2 FRESENIUS KABI AG	98
12.2.1 COMPANY OVERVIEW	98
12.2.2 FINANCIAL OVERVIEW	98
12.2.3 PRODUCTS/SERVICES OFFERED	99
12.2.4 KEY DEVELOPMENTS	99
12.2.5 SWOT ANALYSIS	99
12.2.6 KEY STRATEGIES	100
12.3 B. BRAUN MELSUNGEN AG	101
12.3.1 COMPANY OVERVIEW	101
12.3.2 FINANCIAL OVERVIEW	102
12.3.3 PRODUCTS/SERVICES OFFERED	103
12.3.4 KEY DEVELOPMENTS	103
12.3.5 SWOT ANALYSIS	104
12.3.6 KEY STRATEGIES	104
12.4 ICU MEDICAL, INC.	105
12.4.1 COMPANY OVERVIEW	105
12.4.2 FINANCIAL OVERVIEW	105
12.4.3 PRODUCTS/SERVICES OFFERED	106
12.4.4 KEY DEVELOPMENTS	106
12.4.5 SWOT ANALYSIS	107
12.4.6 KEY STRATEGIES	107
12.5 PFIZER INC.	108
12.5.1 COMPANY OVERVIEW	108
12.5.2 FINANCIAL OVERVIEW	108
12.5.3 PRODUCTS/SERVICES OFFERED	109
12.5.4 KEY DEVELOPMENTS	109
12.5.5 SWOT ANALYSIS	109
12.5.6 KEY STRATEGIES	110
12.6 GRIFOLS, S.A.	111
12.6.1 COMPANY OVERVIEW	111
12.6.2 FINANCIAL OVERVIEW	111
12.6.3 PRODUCTS/SERVICES OFFERED	112
12.6.4 KEY DEVELOPMENTS	112
12.6.5 SWOT ANALYSIS	112
12.6.6 KEY STRATEGIES	113
12.7 TERUMO MEDICAL CORPORATION	114
12.7.1 COMPANY OVERVIEW	114
12.7.2 FINANCIAL OVERVIEW	115
12.7.3 PRODUCTS OFFERED	115
12.7.4 KEY DEVELOPMENTS	116
12.7.5 SWOT ANALYSIS	116
12.7.6 KEY STRATEGIES	116
12.8 OSTUKA PHARMACEUTICALS	117
12.8.1 COMPANY OVERVIEW	117
12.8.2 FINANCIAL OVERVIEW	117
12.8.3 PRODUCTS/SERVICES OFFERED	118
12.8.4 KEY DEVELOPMENTS	118
12.8.5 SWOT ANALYSIS	119
12.8.6 KEY STRATEGIES	119
12.9 AMANTA HEALTHCARE	120
12.9.1 COMPANY OVERVIEW	120
12.9.2 FINANCIAL OVERVIEW	120
12.9.3 PRODUCTS/SERVICES OFFERED	120
12.9.4 KEY DEVELOPMENTS	120
12.9.5 SWOT ANALYSIS	121
12.9.6 KEY STRATEGIES	121
12.10 AXA PARENTERALS	122
12.10.1 COMPANY OVERVIEW	122
12.10.2 FINANCIAL OVERVIEW	122
12.10.3 PRODUCTS/SERVICES OFFERED	122
12.10.4 KEY DEVELOPMENTS	122
12.10.5 SWOT ANALYSIS	123
12.10.6 KEY STRATEGIES	123

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS	16
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS	19
TABLE 3 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION)	33
TABLE 4 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR PERIPHERAL PARENTERAL NUTRITION, BY REGION, 2022-2030 (USD MILLION)	34
TABLE 5 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR TOTAL PARENTERAL NUTRITION, BY REGION, 2022-2030 (USD MILLION)	34
TABLE 6 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION)	35
TABLE 7 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, FOR LARGE VOLUME BAGS (>250 ML), BY REGION 2022-2030 (USD MILLION)	36
TABLE 8 GLOBAL INTRAVENOUS SOLUTIONS MARKET, FOR SMALL VOLUME BAGS, BY REGION 2022-2030 (USD MILLION)	36
TABLE 9 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION)	37
TABLE 10 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR AMINO ACID SOLUTION, BY REGION, 2022-2030 (USD MILLION)	38
TABLE 11 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR CARBOHYDRATES, BY REGION, 2022-2030 (USD MILLION)	38
TABLE 12 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR VITAMINS & MINERALS, BY REGION, 2022-2030 (USD MILLION)	39
TABLE 13 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR PARENTERAL LIPID EMULSION, BY REGION, 2022-2030 (USD MILLION)	39
TABLE 14 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR OTHERS, BY REGION, 2022-2030 (USD MILLION)	40
TABLE 15 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER 2022-2030 (USD MILLION)	41
TABLE 16 GLOBAL INTRAVENOUS (IV) SOLUTION MARKET FOR HOSPITAL & CLINICS, BY REGION, 2022-2030 (USD MILLION)	42
TABLE 17 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2022-2030 (USD MILLION)	42
TABLE 18 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET FOR HOME CARE, BY REGION, 2022-2030 (USD MILLION)	43
TABLE 19 GLOBAL: INTRAVENOUS (IV) SOLUTIONS MARKET, BY REGION, 2022-2030 (USD MILLION)	44
TABLE 20 NORTH AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)	46
TABLE 21 NORTH AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION)	47
TABLE 22 NORTH AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION)	47
TABLE 23 NORTH AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION)	47
TABLE 24 NORTH AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION)	48
TABLE 25 US: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION)	48
TABLE 26 US: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION)	48
TABLE 27 US: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION)	49
TABLE 28 US: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION)	49
TABLE 29 CANADA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION)	49
TABLE 30 CANADA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION)	50
TABLE 31 CANADA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION)	50
TABLE 32 CANADA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION)	50
TABLE 33 EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)	51
TABLE 34 EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION)	52
TABLE 35 EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION)	52
TABLE 36 EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION)	52
TABLE 37 EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION)	53
TABLE 38 GERMANY: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION)	53
TABLE 39 GERMANY: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION)	53
TABLE 40 GERMANY: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION)	54
TABLE 41 GERMANY: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION)	54
TABLE 42 FRANCE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION)	54
TABLE 43 FRANCE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION)	55
TABLE 44 FRANCE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION)	55
TABLE 45 FRANCE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION)	55
TABLE 46 UK: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION)	56
TABLE 47 UK: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION)	56
TABLE 48 UK: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION)	56
TABLE 49 UK: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION)	57
TABLE 50 ITALY: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION)	57
TABLE 51 ITALY: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION)	57
TABLE 52 ITALY: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION)	58
TABLE 53 ITALY: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION)	58
TABLE 54 SPAIN: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION)	58
TABLE 55 SPAIN: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION)	59
TABLE 56 SPAIN: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD	

MILLION) 59
TABLE 57 SPAIN: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 59
TABLE 58 REST OF EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 60
TABLE 59 RST OF EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 60
TABLE 60 REST OF EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 60
TABLE 61 REST OF EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 61
TABLE 62 ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 62
TABLE 63 ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 63
TABLE 64 ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 63
TABLE 65 ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 64
TABLE 66 ASA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 64
TABLE 67 CHINA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 64
TABLE 68 CHINA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 65
TABLE 69 CHINA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 65
TABLE 70 CHINA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 65
TABLE 71 INDIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 66
TABLE 72 INDIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 66
TABLE 73 INDIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 66
TABLE 74 INDIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 67
TABLE 75 INDONESIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 67
TABLE 76 INDONESIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 67
TABLE 77 INDONESIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 68
TABLE 78 INDONESIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 68
TABLE 79 JAPAN: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 68
TABLE 80 JAPAN: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 69
TABLE 81 JAPAN: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 69
TABLE 82 JAPAN: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 69
TABLE 83 PHILIPPINES: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 70
TABLE 84 PHILIPPINES: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 70
TABLE 85 PHILIPPINES: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 70
TABLE 86 PHILIPPINES: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 71
TABLE 87 THAILAND: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 71
TABLE 88 THAILAND: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 71
TABLE 89 THAILAND: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 72
TABLE 90 THAILAND: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 72
TABLE 91 SOUTH KOREA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 72
TABLE 92 SOUTH KOREA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 73
TABLE 93 SOUTH KOREA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 73
TABLE 94 SOUTH KOREA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 73
TABLE 95 AUSTRALIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 74
TABLE 96 AUSTRALIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 74
TABLE 97 AUSTRALIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 74
TABLE 98 AUSTRALIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 75
TABLE 99 SINGAPORE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 75
TABLE 100 SINGAPORE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 75
TABLE 101 SINGAPORE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 76
TABLE 102 SINGAPORE: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 76
TABLE 103 MALAYSIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 76
TABLE 104 MALAYSIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 77
TABLE 105 MALAYSIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION) 77
TABLE 106 MALAYSIA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION) 77
TABLE 107 REST OF ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION) 78
TABLE 108 REST OF ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION) 78

TABLE 109 REST OF ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION)	78
TABLE 110 REST OF ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION)	79
TABLE 111 REST OF THE WORLD: INTRAVENOUS (IV) SOLUTIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)	80
TABLE 112 REST OF THE WORLD: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION)	81
TABLE 113 REST OF THE WORLD: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION)	81
TABLE 114 REST OF THE WROLD: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION)	81
TABLE 115 REST OF THE WORLD: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION)	82
TABLE 116 MIDDLE EAST: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION)	82
TABLE 117 MIDDLE EAST: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION)	82
TABLE 118 MIDDLE EAST: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION)	83
TABLE 119 MIDDLE EAST: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION)	83
TABLE 120 AFRICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION)	83
TABLE 121 AFRICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION)	84
TABLE 122 AFRICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION)	84
TABLE 123 AFRICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION)	84
TABLE 124 LATIN AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION)	85
TABLE 125 LATIN AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION)	85
TABLE 126 LATIN AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION)	85
TABLE 127 LATIN AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION)	86
TABLE 128 COMPETITOR DASHBOARD: GLOBAL INTRAVENOUS SOLUTIONS MARKET	90
TABLE 129 MOST ACTIVE PLAYERS IN THE GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET	91
TABLE 130 PRODUCT LAUNCH/PRODUCT APPROVAL	92
TABLE 131 MERGER/ACQUISITION	92
TABLE 132 PARTNERSHIP/AGREEMENT	93
TABLE 133 EXPANSION/ INVESTMENT	93
TABLE 134 BAXTER INTERNATIONAL INC.: PRODUCTS/SERVICES OFFERED	96
TABLE 135 FRESENIUS KABI AG: PRODUCTS/SERVICES OFFERED	99
TABLE 136 B. BRAUN MELSUNGEN AG: PRODUCTS/SERVICES OFFERED	103
TABLE 137 B. BRAUN MELSUNGEN AG: KEY DEVELOPMENTS	103
TABLE 138 ICU MEDICAL, INC: PRODUCTS/SERVICES OFFERED	106
TABLE 139 ICU MEDICAL, INC.: KEY DEVELOPMENTS	106
TABLE 140 PFIZER INC.: PRODUCTS/SERVICES OFFERED	109
TABLE 141 GRIFOLS, S.A.: PRODUCTS/SERVICES OFFERED	112
TABLE 142 GRIFOLS, S.A: KEY DEVELOPMENTS	112
TABLE 143 TERUMO MEDICAL CORPORATION: PRODUCTS/SERVICES OFFERED	115
TABLE 144 TERUMO MEDICAL CORPORATION: KEY DEVELOPMENTS	116
TABLE 145 OSTUKA PHARMACEUTICALS: PRODUCTS/SERVICES OFFERED	118
TABLE 146 OSTUKA PHARMACEUTICALS: KEY DEVELOPMENTS	118
TABLE 147 AMANTA HEALTHCARE: PRODUCTS/SERVICES OFFERED	120
TABLE 148 AXA PARENTERALS: PRODUCTS/SERVICES OFFERED	122

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS	14
FIGURE 2 GLOBAL INTRAVENOUS (IV) SOLUTION MARKET	15
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES	22
FIGURE 4 MARKET DYNAMICS: GLOBAL INTRAVENOUS SOLUTIONS MARKET	24
FIGURE 5 DRIVERS: IMPACT ANALYSIS	26
FIGURE 6 RESTRAINT: IMPACT ANALYSIS	27
FIGURE 7 VALUE CHAIN: GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET	28
FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL INTRAVENOUS SOLUTIONS MARKET	30
FIGURE 9 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITION TYPE, 2022-2030 (USD MILLION)	33
FIGURE 10 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY BAG TYPE, 2022-2030 (USD MILLION)	35
FIGURE 11 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY NUTRITIONAL CONTENT, 2022-2030 (USD MILLION)	37
FIGURE 12 GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET, BY END USER, 2022-2030 (USD MILLION)	41
FIGURE 13 GLOBAL: INTRAVENOUS (IV) SOLUTIONS MARKET, BY REGION 2020 & 2028 (USD MILLION)	44
FIGURE 14 GLOBAL: INTRAVENOUS (IV) SOLUTIONS MARKET SHARE, BY REGION 2020 (%)	45
FIGURE 15 NORTH AMERICA: INTRAVENOUS (IV) SOLUTIONS MARKET SHARE, BY COUNTRY 2020 (%)	46
FIGURE 16 EUROPE: INTRAVENOUS (IV) SOLUTIONS MARKET SHARE, BY COUNTRY 2020 (%)	51
FIGURE 17 ASIA-PACIFIC: INTRAVENOUS (IV) SOLUTIONS MARKET SHARE, BY COUNTRY 2020 (%)	63
FIGURE 18 REST OF THE WORLD: INTRAVENOUS (IV) SOLUTIONS MARKET SHARE, BY COUNTRY 2020 (%)	80
FIGURE 19 MAJOR MANUFACTURERS IN THE GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET	88
FIGURE 20 BENCHMARKING OF MAJOR COMPETITORS	89
FIGURE 21 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL INTRAVENOUS (IV) SOLUTIONS MARKET	90
FIGURE 22 GLOBAL INTRAVENOUS SOLUTIONS MARKET: COMPETITIVE LANDSCAPE	91
FIGURE 23 BAXTER INTERNATIONAL INC.: FINANCIAL OVERVIEW	95
FIGURE 24 BAXTER INTERNATIONAL INC.: SWOT ANALYSIS	97
FIGURE 25 FRESENIUS KABI AG: FINANCIAL OVERVIEW	98
FIGURE 26 FRESENIUS KABI AG: SWOT ANALYSIS	99
FIGURE 27 B. BRAUN MELSUNGEN AG: FINANCIAL OVERVIEW SNAPSHOT	102
FIGURE 28 B. BRAUN MELSUNGEN AG: SWOT ANALYSIS	104
FIGURE 29 ICU MEDICAL, INC.: FINANCIAL OVERVIEW	105
FIGURE 30 ICU MEDICAL, INC: SWOT ANALYSIS	107

FIGURE 31 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 108
FIGURE 32 PFIZER INC: SWOT ANALYSIS 109
FIGURE 33 GRIFOLS, S.A.: FINANCIAL OVERVIEW 111
FIGURE 34 GRIFOLS, S.A.: SWOT ANALYSIS 112
FIGURE 35 TERUMO MEDICAL CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 115
FIGURE 36 TERUMO MEDICAL CORPORATION: SWOT ANALYSIS 116
FIGURE 37 OTSUKA PHARMACEUTICAL CO., LTD: FINANCIAL OVERVIEW SNAPSHOT 117
FIGURE 38 OTSUKA PHARMACEUTICALS: SWOT ANALYSIS 119
FIGURE 39 AMANTA HEALTHCARE: SWOT ANALYSIS 121
FIGURE 40 AXA PARENTERALS: SWOT ANALYSIS 123